High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Carnitine for the Treatment of Atherosclerosis.

Condition:   Metabolic Syndrome
Interventions:   Dietary Supplement: L-carnitine capsules;   Dietary Supplement: Lactose capsules
Sponsors:   Queen's University;   Heart and Stroke Foundation of Canada
Not yet recruiting - verified April 2014

Pharmacokinetics And Relative Bioavailability Of PF-04950615 When Administered To The Abdomen, Thigh Or Upper Arm

Condition:   Hypercholesterolemia
Interventions:   Device: PF-04950615;   Biological: PF-04950615;   Biological: PF-04950615
Sponsor:   Pfizer
Not yet recruiting - verified April 2014

Dose Ranging Study Of PF-04950615 In Hypercholesterolemic Japanese Subjects

Condition:   Hypercholesterolemia
Interventions:   Drug: PF-04950615;   Drug: PF-04950615;   Drug: PF-04950615;   Drug: Placebo;   Drug: Ezetimibe;   Drug: PF-04950615;   Drug: PF-04950615;   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Not yet recruiting - verified April 2014

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727) Dose Regimen A;   Drug: alirocumab SAR236553 (REGN727) Dose Regimen B;   Drug: alirocumab matching placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Condition:   Hyperlipidemia
Interventions:   Drug: Part A, Atorvastatin;   Other: Part A, Placebo (administered orally);   Drug: Part B, Evolocumab;   Other: Part B, Placebo (administered orally);   Drug: Part B, Ezetimibe;   Other: Part B, Placebo (administered subcutaneously);   Drug: Part C, Evolocumab
Sponsor:   Amgen
Recruiting - verified April 2014

A 52 Week Study To Assess The Use Of RN316 (PF-04950615) In Subjects With Heterozygous Familial Hypercholesterolemia

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: PF-04950615;   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Randomized Clinical Trial of RN316 (PF-04950615) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: PF-04950615;   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Randomized Clinical Trial Of RN316 (PF-04950615) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: PF-04950615;   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Actual Use Trial of Atorvastatin Calcium 10 mg

Condition:   Hypercholesterolemia
Intervention:   Drug: Atorvastatin calcium 10 mg
Sponsor:   Pfizer
Recruiting - verified April 2014

Open Label Study of Long Term Safety Evaluation of Alirocumab

Condition:   Hypercholesterolemia
Intervention:   Drug: Alirocumab SAR236553 (REGN727)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)

Condition:   Hypercholesterolemia
Interventions:   Drug: Anacetrapib;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Open Label Study of Long Term Evaluation Against LDL-C Trial-2

Condition:   Hyperlipidemia and Mixed Dyslipidemia
Interventions:   Drug: evolocumab (AMG 145) and standard of care;   Other: Standard of care
Sponsor:   Amgen
Recruiting - verified April 2014

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Condition:   Hypercholesterolemia
Interventions:   Drug: Evolocumab (AMG 145);   Other: Placebo
Sponsor:   Amgen
Recruiting - verified April 2014

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Condition:   Hyperlipidemia
Interventions:   Drug: Evolocumab (AMG 145);   Other: Placebo
Sponsor:   Amgen
Completed - verified April 2014

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Device: Evolocumab (AMG 145);   Device: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2014

Glucose Metabolism Disorders and Metabolic Syndrome Before and After Primary Hip and Knee Replacement

Conditions:   Hyperglycemia;   Hypercholesterolemia;   Prolonged Postoperative Pain;   Hip Replacement;   Knee Replacement
Intervention:  
Sponsors:   Coxa, Hospital for Joint Replacement;   University of Tampere;   Tampere University Hospital
Active, not recruiting - verified April 2014

U of A/ U of M Beans and Peas Health Claim Project

Condition:   Hypercholesterolemia
Interventions:   Dietary Supplement: Beans;   Dietary Supplement: Control (rice);   Dietary Supplement: Peas
Sponsors:   University of Alberta;   Alberta Innovates Health Solutions;   Pulse Canada;   University of Manitoba
Recruiting - verified April 2014

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: matching placebo alirocumab SAR236553 (REGN727);   Drug: Ezetimibe;   Drug: matching placebo for Ezetimibe
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified April 2014

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Condition:   Homozygous Familial Hypercholesterolemia
Interventions:   Biological: Evolocumab (AMG145);   Biological: Evolocumab (AMG145);   Other: Placebo
Sponsor:   Amgen
Completed - verified April 2014

Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease

Conditions:   Kawasaki Disease;   Aneurysm, Coronary
Intervention:   Drug: Atorvastatin
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Recruiting - verified April 2014

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

Conditions:   HIV;   Hyperlipidemia;   Hypertriglyceridemia;   HIV Infections
Intervention:   Drug: raltegravir
Sponsors:   The Miriam Hospital;   Tufts Medical Center;   Merck Sharp & Dohme Corp.
Completed - verified October 2013

Causes and Natural History of Dyslipidemias

Condition:   Dyslipidemias
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

Effectiveness and Cost Impact of a Telecommunications System in COPD

Condition:   Lung Diseases, Obstructive
Intervention:   Procedure: Telephone Monitoring
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Evaluation of Lipoproteins

Conditions:   Hyperlipidemia;   Hyperlipoproteinemia;   Hypolipoproteinemia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients

Condition:   HIV Infections
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified April 2014

Get CardioSmart

You're Invited